What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Rucaparib shows moderate benefit over placebo in terms of progression-free survival (PFS) in the BRCA mutation-negative HRD-positive and HRD-negative populations. However, the overall survival (OS) data is still immature, and while it is likely to work as well as bevacizumab alone, it is not as effective as olaparib plus bevacizumab. This indicates a moderate therapeutic impact.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for rucaparib in the BRCA mutation-negative HRD-positive subgroup are within what NICE considers acceptable, suggesting it is clearly cost-effective under common thresholds. However, the estimates for the HRD-negative subgroup are less favorable, indicating some context-dependent variability.
Is there quality-of-life evidence payers weigh? — Quality of life
The clinical evidence indicates that rucaparib improves quality of life as measured by the EQ-5D-5L questionnaire, with health-state utility values derived from the ATHENA-MONO trial. While the data is not fully reported, the committee concluded that the treatment is likely to provide moderate improvements in HRQoL.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Rucaparib has a very good safety profile with mostly mild to moderate adverse events. The committee noted that serious adverse events are rare, indicating a favorable tolerability compared to existing therapies.
Was the drug compared against what payers expect? — Comparator Selection
Rucaparib was compared with appropriate standard-of-care alternatives, including olaparib plus bevacizumab and bevacizumab alone. However, the indirect comparisons raise some concerns about the robustness of the evidence, particularly regarding the efficacy of bevacizumab at the relevant maintenance dose.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is broadly representative of the intended patient population, with specific focus on BRCA mutation-negative and HRD-positive or HRD-negative subgroups. The committee noted that the inclusion of these subgroups reflects real-world clinical practice.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Rucaparib can be integrated into existing treatment pathways with minor adjustments. The committee noted that it fits well within the current clinical practice for maintenance treatment after first-line chemotherapy.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of rucaparib is manageable, and the committee concluded that it is resource-efficient, particularly for the BRCA mutation-negative HRD-positive subgroup. However, the implications for the HRD-negative subgroup are less favorable.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by a Phase 3 RCT (ATHENA-MONO) with low bias risk. However, the immaturity of OS data and reliance on indirect comparisons introduce some methodological concerns.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding long-term outcomes and the effectiveness of rucaparib compared to other treatments, the committee noted that these uncertainties are manageable and do not preclude a recommendation.
